- ￥1354
- BioLegend
- 116619
- 美国
- 2025年07月04日
- 免疫荧光，流式
- 小鼠
- 小鼠
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体名：
APC anti-mouse H-2Kd
- 抗体英文名：
APC anti-mouse H-2Kd
- 浓度：
0.2 mg/ml
- 应用范围：
免疫荧光，流式
- 宿主：
小鼠
- 供应商：
上海善然生物
- 库存：
现货
- 抗原来源：
小鼠
- 保质期：
2-3年左右
- 适应物种：
小鼠
- 标记物：
APC
- 克隆性：
单克隆
- 保存条件：
2-8度
- 形态：
液体
- 规格：
25ug
APC anti-mouse H-2K Antibody
d
SF1-1.1
Catalog# / Size 116619 / 25 µg
116620 / 100 µg
Clone
Regulatory Status RUO
Other Names MHC class I
Isotype Mouse (SJL) IgG2a, κ
Description The SF1-1.1 antibody reacts with the H-2K MHC class I alloantigens expressed on nucleated
cells from mice of the H-2K haplotype. H-2K is involved in antigen presentation to T cells
expressing CD3/TCR and CD8 proteins.
d
d d
Product Details
Verified Reactivity Mouse
Antibody Type Monoclonal
Host Species Mouse
Immunogen BALB/c Mouse cells
Formulation Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation The antibody was purified by affinity chromatography and conjugated with APC under optimal
conditions.
Concentration 0.2 mg/ml
Storage & Handling The antibody solution should be stored undiluted between 2°C and 8°C, and protected from
prolonged exposure to light. Do not freeze
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验更多产品详细信息欢迎来电咨询~周祥15900853496（微信同号)，汪海洋15901695283(微信同号)
Anti-Factor H Autoantibodies Assay
of autoantibodies directed against Factor H (FH), the main plasmatic alternative complement pathway regulatory protein. Their presence induces an acquired functional FH deficiency. The anti-FH autoantibodies screening must be performed at the very onset
的同聚核苷酸锚定序列。利用第二个巢式GSP和一个与同聚核苷酸尾巴可以退火的锚定引物来扩增cDNA的5＇末端。用SUPERSCRIPTTM II RT从mRNA复制成cDNA用RNase H和RNase T1降解RNA用GLASSMAXò Spin Cartridge纯化cDNA用dCTP和TdT给纯化的cDNA加尾用精简的锚定引物和巢式GSP2 PCR扩增dC加尾的cDNA 用AUAP和巢式GSP重新扩增初步PCR产物最初的5＇RACE系统是按照这个方法进行的，它首先利用SUPERSCRIPT™
Adenoviral-Mediated Anti-H-ras Ribozyme for the Treatment of Bladder Cancer
Bladder cancer is the fifth most common malignancy, demonstrated by the approx 52,900 patients that will be diagnosed in the United States in 1996 (1 ). Around 15–20% of these patients will be characterized by muscle invasion or node posmve
技术资料暂无技术资料 索取技术资料
